panelarrow

| 0 comments

Of imatinib mesylate and gemcitabine in patients with refractory solid tumor
Of imatinib mesylate and gemcitabine in patients with refractory solid tumor malignancy. ASCO Meeting Abstracts 2005, 23(16_suppl):3100. Lilenbaum RC, Herndon JE, List MA, Desch C, Watson DM, Miller AA, Graziano SL, Perry MC, Saville W, Chahinian P, et al: Single-agent versus combination chemotherapy in advanced non mall-cell lung cancer: the MK-5172 side effects cancer and leukemia group B (study 9730). J Clin Oncol 2005, 23(1):190?96. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, Non-small Cell Lung Cancer, Version 3. 2012. Available at www. nccn.org. Arias-Pulido H, Smith HO, Joste NE, Bocklage T, Qualls CR, Chavez A, Prossnitz ER, Verschraegen CF: Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol 2009, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28607003 114(3):480?85. Saliba D, Elliott M, Rubenstein LZ, Solomon DH, Young RT, Kamberg CJ, Roth C, MacLean CH, Shekelle PG, Sloss EM, et al: The vulnerable elders survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001, 49(12):1691?699.Bauman et al. BMC Cancer 2012, 12:449 http://www.biomedcentral.com/1471-2407/12/Page 8 of26. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373?83. 27. Min L, Yoon W, Mariano J, Wenger NS, Elliott MN, Kamberg C, Saliba D: The vulnerable elders-13 survey predicts 5-year functional decline and mortality outcomes in older ambulatory care patients. J Am Geriatr Soc 2009, 57(11):2070?076. 28. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferrau F, Piazza E, Rosetti F, et al: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003, 95(5):362?72. 29. Gridelli C: The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 2001, 1(6 Suppl):4?. 30. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, et al: Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2011, 6(12):2104?111. 31. Huang CH, Williamson SK, Van Veldhuizen PJ, Hsueh CT, Allen A, Tawfik O, Wick J, Smith H, Uypeckcuat AM, Mayo M, et al: Potential role of plateletderived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2011, 6(2):372?77. 32. Yardley DA, Burris HA 3rd, Markus T, Spigel DR, Greco FA, Mainwaring M, Waterhouse DM, Webb CD, Hainsworth JD: Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer. Clin Breast Cancer 2009, 9(4):237?42. 33. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, et al: Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer wi.

Leave a Reply